Background and Purpose-We sought to model the effects of interhospital transfer network design on endovascular therapy eligibility and clinical outcomes of stroke because of large-vessel occlusion for the residents of a large city. Methods-We modeled 3 transfer network designs for New York City. In model A, patients were transferred from spoke hospitals to the closest hub hospitals with endovascular capabilities irrespective of hospital affiliation. In model B, which was considered the base case, patients were transferred to the closest affiliated hub hospitals. In model C, patients were transferred to the closest affiliated hospitals, and transfer times were adjusted to reflect full implementation of streamlined transfer protocols. Using Monte Carlo methods, we simulated the distributions of endovascular therapy eligibility and good functional outcomes (modified Rankin Scale score, 0-2) in these models. E ndovascular therapy is an effective treatment for ischemic stroke caused by large-vessel occlusion. 1 However, this therapy is not uniformly available.
3
The American Heart Association/American Stroke Association 4 and endovascular trialists 5 have recommended the establishment of interhospital transfer protocols while acknowledging the need to accommodate the unique needs of individual regions and healthcare systems. As seen in the case of the Madrid Stroke Network, strategic design of stroke systems of care in major urban areas can dramatically increase access to endovascular therapy and improve stroke outcomes for large populations. 6 Modeling studies, which can yield insights into the interplay of individual factors in complex systems of care, [7] [8] [9] [10] [11] have demonstrated that travel time is an important factor in acute stroke care that should be accounted for when optimizing systems of care. 12 We sought to model the effects of interhospital transfer network design on travel times, endovascular therapy eligibility, and anticipated clinical outcomes for the residents of New York City. We used publicly available and previously published data in a Monte Carlo simulation to compare these outcome parameters in 3 competing interhospital transfer network designs. The simulation was designed primarily to determine the population-level implications of bypassing unaffiliated hospitals capable of endovascular therapy when transferring patients with large-vessel occlusion for endovascular therapy. We additionally simulated the effects of implementing timesaving transfer protocols when restricting transfers to affiliated hospitals.
Materials and Methods

Design
The data that support the findings of this study are available from the corresponding author on reasonable request. We performed a Monte Carlo simulation to characterize 3 competing transfer network designs in New York, NY. New York City is a dense city with a population of 8.5 million people. 13 The simulation ( Figure 1 ) required several key input parameters that pertain to transferring patients with stroke from nonendovascular-capable (spoke) hospitals to endovascular-capable (hub) hospitals. These inputs were stroke volume at each spoke hospital, percentage of patients with stroke eligible for endovascular therapy before transfer, transfer time (including travel time), the effect of transfer delays on eligibility for endovascular therapy after transfer, and expected functional outcomes among patients receiving and not receiving endovascular therapy. The unit of analysis was each spoke hospital in New York City, and the simulation's outputs were the number of patients eligible for endovascular therapy after transfer and number of patients achieving a good functional outcome. The Monte Carlo simulation inputs were defined using publicly available and previously published data. Additionally, we used data from the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project to choose hospitals to include in our simulation and to estimate each hospital's stroke volume. The Healthcare Cost and Utilization Project 14 provides comprehensive, quality-checked, and deidentified patient-level data, including discharge diagnoses, for research purposes. The Weill Cornell Institutional Review Board approved our analysis of these data.
Transfer Network Models
We used real-world data on New York City hospitals to model stroke care for patients requiring interhospital transfer for endovascular therapy. First, using New York State administrative data from the Healthcare Cost and Utilization Project, we identified 49 nonfederal hospitals and emergency departments in New York City with documented discharges for stroke in 2014-the most recent year of available data. We reviewed each hospital's website to determine whether it is a comprehensive stroke center or otherwise provides endovascular therapy for acute ischemic stroke and to determine its official hospital affiliations. There were 34 spoke hospitals without endovascular therapy capabilities and 15 hub hospitals able to perform endovascular therapy. There are numerous large hospital systems in New York City; hospitals within these systems often preferentially transfer patients to other affiliated hub hospitals. Spoke hospitals' affiliations were determined based on explicit website documentation of corporate hospital network membership, clinical affiliation, or academic affiliation, in this order of priority. There are 6 private hospital networks and 1 public hospital system in New York City; some networks have multiple hub hospitals. For each of the 34 spoke hospitals, we identified both the nearest affiliated hub hospital and the nearest hub hospital irrespective of affiliation.
Using this information, we devised 3 competing interhospital transfer network designs. In model A, all patients were transferred from the initial spoke hospital without endovascular therapy capabilities to the closest hub irrespective of hospital affiliation. In model B, which was the base case, all patients were transferred to the closest affiliated hub. These models were designed to investigate the effects of bypassing unaffiliated hub hospitals when transferring solely among affiliated hospitals. In a post hoc analysis, we created an additional transfer network model to investigate the potential effects of Figure 1 . Monte Carlo simulation of 3 competing interhospital transfer network models. We devised 3 competing interhospital transfer network designs (A). We estimated the number of patients eligible for endovascular therapy and thus requiring interhospital transfer at each spoke hospital annually. In base case model B, patients are transferred from the spoke hospital to the nearest affiliated hub hospital. In model A, patients are transferred to the geographically nearest hospital regardless of affiliation. In model C, patients are transferred as in model B, but the transfer time is adjusted to account for implementation of time-saving transfer protocols among affiliated hospitals. The formulae by which input parameters produced estimates of outcomes are shown (B).
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pre-established transfer protocols that may improve overall transfer efficiency among affiliated hospitals. In model C, patients were transferred to the closest affiliated hub hospital as in model B, but overall transfer times were adjusted to account for possible advantages conferred by pre-established transfer protocols.
Population
We used New York state administrative claims data for emergency department visits and hospitalizations at nonfederal acute care facilities in 2014 to estimate each spoke hospital's annual stroke volume. Encounters for stroke were ascertained using a validated International Classification of Diseases, Ninth Revision, Clinical Modification code algorithm. 15 Then, based on Get With The Guidelines-Stroke Registry data, we estimated that 2.6% (interquartile range [IQR], 1.6%-4.4%) of the patients at spoke hospitals would be candidates for endovascular therapy. 16 These patients would require interhospital transfer to a hub hospital for endovascular therapy and thus constituted the study population for our models.
Transfer Times
We used real-world traffic data to estimate travel times for patients undergoing interhospital transfer to hub hospitals. Spoke and hub hospital addresses were reviewed and manually converted into latitude and longitude coordinate pairs using Google Earth. 17 We then developed a Google traffic application that estimated travel times between spoke and hub hospitals using the Google Maps API. 18 This platform allowed us to embed historical traffic data in a Python script that adapted a previously validated interface 19 to accurately approximate travel times. In the primary analysis, we modeled low traffic levels to approximate ambulance travel because ambulances can often bypass traffic. In addition to travel time, total transfer time was modeled to include additional time for care at the initial hospital and transfer logistics, termed the door-in to door-out time. 10 We designed models A and B with the assumption that care and transfer processes are equally efficient regardless of hospital affiliation. However, model C was designed to account for potential asymmetries in transfer processes between affiliated and unaffiliated hospitals. A recent analysis of an acute stroke transfer network in Rhode Island found that full implementation of an agreed-on transfer protocol was associated with reduced transfer times, primarily as a result of a reduction of door-in to door-out times by 39%. 20 Although full implementation was observed in only 31% of cases, we modeled a best-case scenario in which the door-in to door-out time was reduced by 39% for all patients transferred between affiliated hospitals in model C.
Outcomes
We then modeled the effect of transfer model design on endovascular therapy eligibility and anticipated functional outcomes. First, we determined the effect of transfer time on the conditional probability of endovascular therapy eligibility. Based on an analysis of stroke care in a similarly large, dense urban area, 21 we assumed transfer time was a continuous predictor of endovascular therapy eligibility and applied an average 2.5% (95% confidence interval, 0.5%-4.4%) reduction in the odds of receiving endovascular therapy per minute of transfer delay. Consequently, the conditional probability of endovascular therapy eligibility had a sigmoidal functional dependence on transfer time and was estimated using a logistic curve. Then, based on a meta-analysis of endovascular therapy trial data, 1 we modeled the expected proportions of good functional outcomes for patients undergoing and not undergoing endovascular therapy: 46% and 27%, respectively. We applied these findings, which represent the aggregate benefit of endovascular therapy across a spectrum of treatment times, to our simulation. A good functional outcome was defined as a modified Rankin Scale score of 0 to 2 at 90 days.
Statistical Analysis
We performed a Monte Carlo simulation-a modeling approach that has been used-to model other aspects of acute stroke care. 9, 22 We chose the Monte Carlo method, specifically second-order Monte Carlo simulation because it allowed us to estimate the distribution of desired outcomes by accounting for the uncertainty in each input parameter. 23 For each iteration, a single estimate from the probability distribution of each input parameter is drawn. These parameters are then used to calculate an estimate of a desired outcome. The distributions of the outcomes are generated after several thousand iterations; in our analysis, we performed 10 000 iterations of the 3 interhospital transfer network models. The key input parameters described in our simulations were all derived using previously published and clinically reasonable estimates (Table) . From these simulations, we report the median number of patients transferred per spoke hospital. In aggregate, we report the median number of patients eligible for endovascular therapy after transfer and the median number of patients achieving a good functional outcome in each of the 3 interhospital transfer network models. Uncertainty is reported as IQR. The number of patients needed to be transferred to yield 1 additional patient eligible for endovascular therapy and 1 additional patient achieving a good functional outcome was also calculated by dividing the total number of patients transferred in each simulation by the difference between models for each outcome. We used kernel density estimation to visualize the distributions of our outcomes. To achieve a margin of error of 0.01, we performed 10 000 total simulations. The Monte Carlo simulation was modeled in R (v3.2.3) by AC and ID. 24 
Sensitivity Analyses
We performed several 1-way sensitivity analyses to understand how our simulation varied with changes to the point estimates of input parameters. We individually tested plausible extremes of the following input variables: pretransfer endovascular therapy eligibility, doorin to door-out times, travel times under extreme traffic conditions, door-in to door-out time reduction achieved through implementation 
Results
Based on administrative data, 7482 patients with acute ischemic stroke are cared for at 34 spoke hospitals in New York City each year. Of these, 200 (IQR, 168-227) patients have strokes amenable to endovascular therapy and thus require transfer to hub hospitals. In our simulation, spoke hospitals would each transfer a median of 5 (IQR, 4-7) patients per hospital annually. The geographically closest hub hospital was an affiliated hospital for 14 (41%) of the spokes, whereas the geographically closest hub hospital was an unaffiliated hub hospital for 20 (59%) of the spokes. The mean travel distance from spoke hospitals to the closest hub was 7.0 (IQR, 3.3-9. The results of 1-way sensitivity analyses revealed the relative strengths of the different transfer network designs under a range of conditions. Imputing a higher baseline, pretransfer endovascular therapy eligibility rate had the most substantial effect on absolute outcomes because the throughput of all models increased. Apparent differences between transfer network designs, however, remained similar. Simulating higher door-in to door-out times revealed better patient outcomes in model C because affiliated hospitals with prearranged transfer protocols had an advantage in these conditions. When the effect of such transfer protocols was more modest, the differences in outcomes for model C, compared with A and B, were attenuated. In high traffic conditions, differences between models A and B appeared greater, likely because shorter travel distances in model A were more beneficial in these conditions. Last, the simulation was sensitive to the time dependence of endovascular therapy eligibility after transfer; differences between models were attenuated when time had a weaker association with the odds of receiving endovascular therapy after transfer. Exact results are tabulated in the Materials in the online-only Data Supplement.
Discussion
Using a Monte Carlo simulation of acute stroke care in a dense urban area with a large number of hospitals, we found that an interhospital transfer model that minimized transfer distances within a drip-and-ship paradigm reduced travel times and resulted in a small increase in the number of patients receiving endovascular therapy and achieving good clinical outcomes at a population level. Modeling the effects of full implementation of time-saving transfer protocols between affiliated hospitals was also associated, to a greater extent, with an increased number of patients receiving endovascular therapy and achieving good clinical outcomes.
We used real-world data and realistic, physiological assumptions, and the results of our model are comparable with limited real-world data from 2 large metropolitan areas. Among 132 patients transferred for endovascular therapy from 33 regional hospitals to a single hospital in Chicago, IL, only 14% were ineligible for endovascular therapy on arrival due specifically to the elapsed time. 21 Similarly, among 120 patients transferred within an interhospital transfer network in Madrid, Spain, transfer delay was a rare cause of treatment ineligibility. 26 The majority of exclusions from endovascular therapy after transfer were because of clinical reasons in both studies. The likelihood of endovascular therapy after transfer in our study was higher than that reported in these 2 cities, which is plausible given expected secular trends in overall systems of stroke care. Because New York City has a high population density, travel distances between hospitals in our model were relatively small as compared with Chicago, where the median distance was 14.7 miles. 21 This, in part, may explain the small effect size of minimizing transfer distances on travel times and eligibility rates in our models.
There is ample evidence that interhospital transfer is associated with increased time from onset to reperfusion 27, 28 and that delays in reperfusion are associated with worse clinical outcomes. 3, 29, 30 Although the outcomes of models A and B were not markedly different, transfer times were decreased in model A, and clinical outcomes were slightly improved. Attention to travel distances and times unsurprisingly appears to be important for optimizing stroke systems of care. 7, 12 However, agreed-on interhospital transfer protocols can reduce transfer
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times and improve clinical outcomes, 20 and modeling such system improvements appeared to increase access to endovascular therapy and improve outcomes in our model as well and to a larger degree. As such, optimizing transfer network design may entail multiple synergistic approaches, including reductions in transfer distances and implementation of universal transfer protocols regardless of hospital affiliation. Indeed, strategic efforts to improve individual aspects of stroke systems of care have yielded meaningful gains in overall outcomes. 6, 31, 32 Further, investigators have demonstrated the populationlevel benefit of improved stroke systems of care. 33, 34 Datadriven approaches to optimize systems of stroke care are rare given the paucity of system-wide population data and care metrics. As an alternative, modeling approaches have been used to identify opportunities for improvement. Our simulation did not account for emerging modeling evidence of the population benefit of alternatives to the current drip-andship paradigm. Chiefly, the population-level effectiveness of mobile stroke units 9 and the direct to comprehensive stroke center (mothership) approach 10, 11 have been demonstrated in modeling, and real-world evaluations have begun. 35 The direct to comprehensive stroke center approach may gain traction particularly if the lack of benefit of intravenous thrombolysis in patients undergoing endovascular therapy 36 is further supported, although this will have to account for the fact that the Figure 2 . Probability distributions of endovascular eligibility and good stroke outcomes in 3 competing interhospital transfer network models. Probability distributions of endovascular therapy eligibility and good functional outcomes for patients being transferred for endovascular stroke therapy in New York City as modeled by Monte Carlo simulation. The probability distributions of endovascular therapy eligibility (A) and good functions outcomes (C) in models A and B were similar. The probability distributions of both outcomes in model C appeared right shifted compared with model B (B and D) . A good outcome was defined as modified Rankin Scale score 0 to 2.
vast majority of patients with stroke are not eligible for endovascular therapy.
Limitations
First, we assumed that patients were transferred in a dripand-ship model, despite emerging evidence on mobile stroke units and the direct to comprehensive stroke center approach. However, these approaches are largely experimental and have not yet become widespread given financial and other logistical concerns. Second, our models did not account for potential categorical differences in prehospital care of patients presenting to spoke versus hub hospitals. However, with model C, we accounted for potential differences in transfer protocols between affiliated and nonaffiliated hospitals. Third, we did not include measures of cost-effectiveness, particularly with regards to developing transfer infrastructure between unaffiliated hospitals. Fourth, the results of our model may not generalize to other cities. As was the case in our models, the differences in performance of stroke network designs will be influenced by hospital density. The results of our models and our analytic approach may be germane to stroke systems of care in similarly large metropolitan areas. Last, some of the assumptions of our model were not derived from population-based data for New York City but instead from clinical trials and observational studies in other locales. The results of the 1-way sensitivity analyses suggest that the simulation outputs vary over a range of input parameter estimates; these analyses reveal relative strengths of the different transfer network designs in different conditions. Although we believe our assumptions to be fair and imputed with sufficient estimates of uncertainty, the results of our model cannot substitute for analysis of carefully collected patient data. We hope improved metrics specific to interhospital transfer will facilitate such analyses.
Conclusions
Our modeling for New York City suggested that transferring patients with acute stroke from large-vessel occlusion to the closest hub hospital irrespective of hospital affiliation, or fully implementing transfer protocols among affiliated hospitals, could improve eligibility for endovascular therapy and clinical outcomes. Perhaps, because of the density of New York City and the multifactorial nature of endovascular therapy eligibility, differences between transfer network models were small. Other strategies to improve access to timely endovascular therapy for patients requiring interhospital transfer deserve investigation.
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